Biomedical Catalyst Accelerator Provider Pool (Late Stage): 2026 Closed EOI and Provider Guide
A historical guide to Innovate UK’s closed 2026 expression of interest for experienced providers of late-stage Biomedical Catalyst and wider health and life sciences accelerator programmes.
Biomedical Catalyst Accelerator Provider Pool (Late Stage): 2026 Closed EOI and Provider Guide
The late-stage Biomedical Catalyst Accelerator Provider Pool expression of interest (EOI) is closed. Innovate UK opened the competition on 2 February 2026 and the deadline was 4 March 2026 at 11:00am UK time. The official Innovation Funding Service page says that the competition is now closed, and the UKRI opportunity page carries the same status and closing time. No later cycle or replacement deadline is announced on the official pages checked for this update.
This page is therefore a historical reference, not a live invitation to apply. The deadline field retains the genuine closing date for the completed round, while historicalReference = true tells the site that the closed listing is an archive entry. The official UKRI page remains useful because it documents the provider-pool model and links to the full Innovation Funding Service brief. It does not reopen the competition, and a provider should not treat the presence of the link as permission to submit after the deadline.
Verified facts at a glance
| Detail | Official information for the completed EOI |
|---|---|
| Programme | Biomedical Catalyst (BMC) Accelerator Provider Pool, late-stage strand |
| Operator | Innovate UK, part of UK Research and Innovation (UKRI) |
| Status | Closed historical competition |
| Opening date | 2 February 2026 |
| Closing date | 4 March 2026 at 11:00am UK time |
| EOI funding | None; the EOI selected providers for a pool rather than awarding project funding |
| Potential future programme cost | Up to £500,000 per accelerator programme for 10-15 participants, according to the competition brief |
| Applicant model | One lead applicant; consortia were not permitted |
| Provider-pool horizon | Providers could be called upon over a period of up to three years |
| Official source | UKRI opportunity page and the linked Innovation Funding Service competition |
The distinction between the EOI and future delivery is important. The UKRI summary displays a total fund of £500,000, but the detailed Innovation Funding Service brief states plainly that there was no funding in this EOI competition. The detailed figure describes the expected cost of a future accelerator programme, not a grant cheque for an organisation that submitted an expression of interest. Innovate UK also states that future eligible project costs would be 100% funded if a provider were later called upon under the pool. That future work was conditional on selection, programme need, and a subsequent call-off; joining the pool did not guarantee paid work.
What the competition was for
Innovate UK sought experienced organisations that could be placed in an approved provider pool for Biomedical Catalyst Accelerator delivery. The pool was intended to support the BMC brand and, where appropriate, wider Innovate UK health and life sciences accelerator programmes. Providers could be called upon when a programme theme and delivery requirement matched their capability. The brief describes a multi-year arrangement, with providers supporting cohorts of UK-based life sciences SMEs and helping them develop credible propositions that could progress toward feasibility-stage R&D funding.
This was not an ordinary research grant competition. The applicant was not asking Innovate UK to fund its own biomedical experiment, product development plan, or clinical study. It was proposing a structured accelerator service: a defined way to recruit and support innovative SMEs, a team able to deliver the work, a credible operating model, and evidence that earlier programmes had produced measurable results.
The late-stage strand was aimed at innovative human health SMEs that were further along than an ideation or early validation programme. The official brief lists relevant late-stage support areas as scale-up, investment readiness, regulatory and reimbursement strategy, market access, and commercial growth. A provider could focus on one or several of these areas, but the application needed to show a coherent accelerator offer and relevant past delivery rather than a generic list of consultancy services.
Eligibility for the completed round
The competition accepted one application from a single organisation. Consortia were not permitted. The eligible lead-organisation categories were broad: a UK-registered business of any size, an academic institution, a charity, a not-for-profit organisation, a research and technology organisation, or a public sector organisation. The applicant had to be able to deliver a Biomedical Catalyst Accelerator Programme if selected, operate at arm’s length from Innovate UK and UKRI in delivering accelerators and innovation programmes, and carry out delivery activities primarily in the UK.
The applicant also needed to intend to support UK-registered innovative SMEs and to demonstrate a proven track record of designing and delivering an end-to-end, structured accelerator for innovative micro, small and medium-sized enterprises. Evidence needed to cover previous delivery, including scale, duration, and measurable outcomes. Capacity mattered as well: the organisation had to be able to mobilise support services when called upon during the life of the approved provider pool.
Subcontractors were allowed. The lead applicant remained accountable, and subcontractors had to be selected through the applicant’s usual procurement process. UK subcontractors were the expected route. An overseas subcontractor required a detailed explanation of why a UK option was not available, evidence of the UK contractors approached, and reasons those contractors could not work on the programme. Cost alone was not accepted as a sufficient reason for using an overseas subcontractor.
The brief also set boundaries around public support. Innovate UK would not select providers without evidence of structured accelerator delivery and measurable impact, or proposals that were not tailored to biomedical and healthcare R&D SMEs. It excluded delivery that would cause double funding from Innovate UK or UKRI, organisations whose core funding came directly from Innovate UK or UKRI for similar business-support activity, projects classed as State aid or a subsidy under the cited rules, and undertakings that would gain a selective commercial or economic advantage from the outputs.
What a late-stage provider needed to offer
The programme themes covered a wide range of biomedical and healthcare R&D. The brief names advanced therapies such as cell, gene, RNA, and regenerative technologies; biosciences and platform technologies; preclinical tools and target discovery; therapeutics and medicine development, including antimicrobial resistance and infectious disease; diagnostics and biomarkers; medical technologies, devices and robotics; precision and personalised medicine; digital and data-driven health; and healthy ageing and independent living.
That list was not a request to claim expertise in every field. A credible provider would define the areas it could support well, explain how its team would handle specialist needs, and show how the programme would adapt to the participants selected. For a late-stage cohort, useful support might include a scale-up decision plan, an investment-readiness workstream, a regulatory and reimbursement evidence map, a market-access pathway, or structured commercial-growth work. The application needed to connect those activities to participant outcomes, not merely name them.
Innovate UK expected future accelerators to support 10-15 participants per programme with total costs up to £500,000. The brief also required providers to explain how delivery would be mobilised efficiently, how they would work with Innovate UK and other delivery partners, and how they would monitor, evaluate, and report outputs and outcomes. Innovate UK could use a portfolio approach when appointing providers, balancing capability, expertise, technology coverage, and stages of business development. Selection was consequently competitive: a strong score alone did not guarantee entry into the pool.
How the application worked
The completed application was submitted through the Innovation Funding Service. The portal divided the work into project details and application questions. Applicants first identified the application team, gave the proposed programme title and availability, and supplied a programme summary, public description, and scope statement. Each of those narrative fields allowed up to 400 words. The portal instructed applicants not to include website addresses in their answers; adding URLs could make an application ineligible.
The scored questions required a practical delivery case. The main areas were:
- Programme management and implementation. Applicants had to describe the structure and delivery of the accelerator under the Biomedical Catalyst brand, including cohort management, curriculum design, SME engagement, work packages, duration, leads, costs, delivery location, and relevant previous biomedical or healthcare accelerator experience.
- Project team and subcontractors. The response covered roles, skills, experience, facilities, resources, critical subcontractors, planned recruitment, and the innovation ecosystem of investors, industry partners, clinicians, regulators, and trade associations.
- Recruitment and assessment. Applicants explained how they would attract and support UK-registered SMEs and spin-outs, judge readiness for a late-stage accelerator, keep selection fair and inclusive, manage conflicts of interest, and evidence participant progression from previous programmes.
- Risks. The application needed to address delivery, SME engagement, regulatory, commercial, and management risks, along with mitigations, critical inputs, and the effect of risk on outcomes.
- Costs and value for money. Applicants set out total eligible costs for a cohort of 10-20 UK SMEs, activity-level costs, subcontractor costs, and why the proposed model represented value for money.
- Evaluation. The response covered success metrics, evaluation criteria, participant feedback, improvement loops, and measurable impact from earlier biomedical or healthcare SME programmes.
The portal allowed supporting appendices for several answers. These could include a programme-activity overview of up to four A4 pages, a team summary of up to four A4 pages, a recruitment appendix of up to two A4 pages, a risk register of up to two A4 pages, and evidence of previous delivery and impact of up to two A4 pages. Each appendix had to be a legible PDF no larger than 10MB. The exact questions and appendix rules belonged to the closed competition brief; a future call could change them.
Timeline and status of the 2026 round
The competition opened on 2 February 2026. An online briefing event was listed for 6 February 2026. Applications closed on 4 March 2026 at 11:00am UK time, and the Innovation Funding Service recorded 8 April 2026 as the applicant-notification date. Those dates describe the completed round. There is no basis in the official source reviewed for changing the page to a rolling deadline, adding a late-submission route, or inventing a new opening date.
The provider-pool structure also means that the end of the EOI does not itself tell a reader which organisations were selected or when a particular future accelerator will be commissioned. Successful applicants were to receive notification and assessor feedback through the Innovation Funding Service. The competition page says that even a well-scoring application might not be approved if it was below the funding threshold or was not selected under the portfolio approach. This page should not imply that any particular provider entered the pool.
How to use this archive entry
An organisation preparing for a future Innovate UK health and life sciences provider call can use this closed brief as a planning reference. Build a concise record of structured programmes already delivered: cohort size, duration, curriculum, team, participant profile, outputs, and measurable outcomes. Keep separate examples for late-stage work such as scale-up, regulatory strategy, reimbursement, market access, investment readiness, and commercial growth. A collection of logos or broad claims about networks will be less useful than two or three cases with clear starting points, actions, and results.
Prepare a delivery model that can be mobilised without turning every cohort into a bespoke experiment. Set out how participants would be recruited, assessed, onboarded, matched to expertise, monitored, and supported after the formal programme. Make the accountability structure visible, especially where subcontractors or external experts are involved. Include conflict-of-interest controls, quality assurance, data handling, safeguarding where relevant, and a process for escalating regulatory or participant risks.
Finally, check the official UKRI opportunity page and any new Innovation Funding Service competition before using this material in an application. A later call may alter the eligible organisation types, participant count, cost ceiling, evidence requirements, strands, or application questions. Until Innovate UK publishes a successor, the 2026 late-stage EOI remains closed and this page should be read as a factual record of that round.
Official source
The authoritative reference is the UKRI opportunity page, which links to the closed Innovation Funding Service competition. Innovate UK operates the competition. Check those pages for any future announcement rather than relying on the historical deadline shown above.